Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter
Full year unaudited revenue from continuing operations of $96.2 million exceeded the high end of the previously raised guidance range for FY2025
BOTHELL, Wash., Jan. 12, 2026 /PRNewswire/ — BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (“CGT”) market, today announced preliminary fourth quarter and full year 2025 unaudited revenue from continuing operations.
Roderick de Greef, BioLife’s Chairman and CEO, commented, “We closed out the year strong with 20% growth in fourth quarter revenue from continuing operations. For the year, revenue from continuing operations increased 29% on a like-for-like basis compared with 2024, largely driven by growth in our biopreservation product line. Following the divestiture of our evo product line in October, we are well positioned as a pure-play cell processing company focused on high-value, recurring revenue franchises. Our streamlined, market-leading product portfolio and strong financial position support our expectations for profitable growth and long-term value creation.
“Looking ahead to 2026, …